Stocks Health care ELV
NYSE · Health careElevance Health, Inc. (ELV)
Elevance Health, Inc. brought in $201.8B of revenue over the twelve months to September 30, 2026, up 3.6% from a year earlier. Net income was $5.1B, a net margin of 2.5%. Operating cash flow minus capital spending left $3.2B of free cash flow in fiscal 2025. At September 30, 2026 it held $10.3B in cash against $30.8B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 21, 2026.
Key facts about Elevance Health, Inc.
- Net worth
- Elevance Health, Inc. has a market value (market cap) of $93.2B at the latest share price, and shareholders' equity of $44.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $199.1B (+12.5% year on year), with net income of $5.7B. Over the 12 months to September 30, 2026: revenue $201.8B, net income $5.1B.
- Cash flow
- In fiscal 2025 operations brought in $4.3B of cash; after $1.1B of capital spending, free cash flow was $3.2B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 21, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Elevance Health, Inc.'s next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Elevance Health, Inc. does
Elevance Health provides commercial, Medicare, and Medicaid health insurance plans as well as integrated health services. It offers medical, pharmacy, dental, and behavioral healthcare coverage to individual consumers, employers, and government program participants. Its shares trade on NYSE under the ticker ELV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $199.1B | $5.7B | $25.21 | $3.2B |
| 2024 | $177B | $6B | $25.68 | $4.6B |
| 2023 | $171.3B | $6B | $25.22 | $6.8B |
| 2022 | $156.6B | $5.9B | $24.28 | $7.2B |
| 2021 | $138.6B | $6.2B | $24.95 | $7.3B |
| 2020 | $121.9B | $4.6B | $17.98 | $9.7B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ELV ranks in Health care
Dividends
It paid out $1.5B in cash dividends, 27% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $1.5B | 27% |
| 2024 | n/a | $1.5B | 25% |
| 2023 | $5.92 | $1.4B | 23% |
| 2022 | $5.12 | $1.2B | 21% |
| 2021 | $4.52 | $1.1B | 18% |
| 2020 | $3.80 | $954M | 21% |
Latest SEC filings
What Elevance Health, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 28, 2026
- October 21, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 1.4% to $51.4B versus the same quarter last year; diluted EPS $6.27 versus $5.32.
- October 21, 2026
- September 10, 2026
- July 15, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 1.4% to $50.5B versus the same quarter last year; diluted EPS $6.71 versus $7.72.
- July 15, 2026
- June 17, 2026
- June 17, 2026
- June 10, 2026
- May 13, 2026
What is ELV worth? A DCF from its reported cash flow
Insider trades
What the people running Elevance Health, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5.2M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Lavu RatnakarEVP & Chief Digital Info Ofr | Sold | 1,300 | $572K |
| October 22, 2026 | Kaye MarkEVP & CFO | Sold | 400 | $173.6K |
| October 22, 2026 | Kaye MarkEVP & CFO | Sold | 321 | $139.7K |
| October 22, 2026 | Kaye MarkEVP & CFO | Sold | 1,660 | $724.1K |
| October 22, 2026 | Kaye MarkEVP & CFO | Sold | 560 | $244.8K |
| October 22, 2026 | Kaye MarkEVP & CFO | Sold | 240 | $105.2K |
| October 22, 2026 | Kaye MarkEVP & CFO | Sold | 1,160 | $509.5K |
| October 22, 2026 | Kaye MarkEVP & CFO | Sold | 1,720 | $757.6K |
Who owns ELV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.13% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,604 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 18,991,090 | -896,021 |
| Vanguard Capital Management LLC | 14,058,204 | -287,255 |
| State Street Corp | 10,426,610 | +137,914 |
| Wellington Management Group Llp | 9,213,513 | +984,976 |
| First Eagle Investment Management, LLC | 8,376,392 | +4,244,101 |
| Vanguard Portfolio Management LLC | 6,214,356 | -141,721 |
| Sanders Capital, LLC | 5,825,024 | -69,279 |
| Geode Capital Management, LLC | 5,166,124 | -26,583 |
| Harris Associates L P | 4,924,511 | +127,985 |
| Artisan Partners Limited Partnership | 4,581,222 | -545,953 |
| Invesco Ltd. | 4,234,231 | -583,179 |
| Norges Bank | 3,958,856 | new |
| Bank of New York Mellon Corp | 3,222,787 | +377,507 |
| Fmr LLC | 3,131,652 | +1,155,933 |
| Morgan Stanley | 2,605,764 | -23,340 |
| Northern Trust Corp | 2,114,986 | -43,039 |
| Citigroup Inc | 2,096,863 | +1,858,013 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,065,537 | -453,078 |
| Hotchkis & Wiley Capital Management LLC | 2,016,200 | -175,363 |
| Goldman Sachs Group Inc | 2,005,613 | +529,430 |
Insiders
19 insiders reported holding 365,066 shares in total, about $156.9M at the last price.
| Holder | Shares |
|---|---|
| Boudreaux GailPresident and CEO, Director | 171,976 |
| Norwood Felicia FEVP &Chief Health Benefits Ofr | 38,838 |
| Haytaian Peter DEVP & Pres Carelon & CarelonRx | 27,222 |
| Kaye MarkEVP & CFO | 19,919 |
| Lavu RatnakarEVP & Chief Digital Info Ofr | 14,849 |
| Hay Lewis IIIDirector | 12,070 |
| Kendrick Charles Morgan JREVP & President, Commercial | 11,791 |
| Peru Ramiro GDirector | 10,908 |
| Dixon Robert L JRDirector | 10,734 |
| Wessling Erin MEVP & Chief Legal Officer | 7,230 |
Questions about ELV
What does Elevance Health, Inc. do?
Elevance Health provides commercial, Medicare, and Medicaid health insurance plans as well as integrated health services. It offers medical, pharmacy, dental, and behavioral healthcare coverage to individual consumers, employers, and government program participants. Its shares trade on NYSE under the ticker ELV.
What is Elevance Health, Inc.'s net worth?
Elevance Health, Inc. has a market value (market cap) of $93.2B at the latest share price, and shareholders' equity of $44.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Elevance Health, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $5.1B on revenue of $201.8B, a net margin of 2.5%.
How much revenue does Elevance Health, Inc. make?
Over the twelve months to September 30, 2026 Elevance Health, Inc. reported revenue of $201.8B. That is 3.6% more than a year earlier.
When did Elevance Health, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 21, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Elevance Health, Inc.'s next earnings report?
Elevance Health, Inc.'s next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ELV with
Follow ELV
Get an email when Elevance Health, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Elevance Health, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.